Cutler Group LP Intellia Therapeutics, Inc. Put Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2023 Jul 18, 2023	BUY	$34.58 - $46.03 $31,122 - $41,427	900 Added 900.0%	1,000 $7,000
Q4 2022 Feb 07, 2023	SELL	$33.21 - $62.69 $358,668 - $677,052	-10,800 Reduced 99.08%	100 $6,000
Q3 2022 Oct 25, 2022	BUY	$53.92 - $71.7 $231,856 - $308,310	4,300 Added 65.15%	10,900 $227,000
Q1 2022 Apr 14, 2022	BUY	$58.27 - $118.99 $378,755 - $773,435	6,500 Added 6500.0%	6,600 $177,000
Q4 2021 Jan 18, 2022	SELL	$100.76 - $138.36 $1.71 Million - $2.35 Million	-17,000 Reduced 99.42%	100 $3,000
Q2 2021 Jul 19, 2021	BUY	$60.88 - $161.91 $1.04 Million - $2.77 Million	17,100 New	17,100 $69,000
Q3 2018 Nov 07, 2018	SELL	$25.78 - $32.6 $30,936 - $39,120	-1,200 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$20.02 - $30.79 $22,022 - $33,869	-1,100 Reduced 47.83%	1,200 $0
Q1 2018 May 11, 2018	BUY	$19.43 - $34.95 $21,373 - $38,445	1,100 Added 91.67%	2,300 $19,000
Q4 2017 Jan 17, 2018	SELL	$17.39 - $31.12 $370,407 - $662,856	-21,300 Reduced 94.67%	1,200 $6,000
Q3 2017 Oct 17, 2017	BUY	$15.16 - $25.75 $341,100 - $579,375	22,500	22,500 $24,000

317

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $835M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.